Royalty Pharma plc (RPRX) continues to be in limelight for variety of financial actions and operations. Making major financial strides, the company recently entered into a $150 Million Royalty Funding Agreement with both Ascendis Pharma and Cytokinetics. However, Ascendis stock fell 12% amid lowered outlook and this royalty deal. Several asset management firms including New South Capital Management Inc. and Torray Investment Partners LLC have raised their stakes in the Pharma company. Investment commentators have suggested it as a solid defensive pick. Royalty Pharma has reported second Quarter 2024 results, indicating Q2's EPS beat expectations while revenues lagged. Despite subsequent stock movements and financials shown by the company, insiders sold off around US$44m in shares, indicating hesitancy. The leverage of the company was also on scrutiny with significant debt utilization being highlighted. Royalty Pharma showcased its second quarter robust growth and raised its 2024 outlook pushing its position to 'Buy'. Recent moves by Buffett's Berkshire indicate significant interest in the drug royalty company.
Royalty Pharma Stocks News Analytics from Tue, 16 Jun 2020 07:00:00 GMT to Sun, 08 Sep 2024 11:40:22 GMT -
Rating 2
- Innovation -3
- Information 6
- Rumor -1
